

How GTSN Saved an Employer Over \$800K on a Single Member's Tepezza Infusions

The Problem

Tepezza, a specialty medication used to treat Thyroid Eye Disease (TED), is administered once every three weeks for a total of eight doses, and when delivered through outpatient hospital facilities often incurs significant buy-and-bill markups.

When one patient covered under a GTRx managed plan began receiving Tepezza infusions in an outpatient setting, the high treatment costs threatened the plan's financial sustainability.

The Solution

GTRx quickly identified the case for intervention and conducted a rapid assessment. GTRx confirmed the patient met the criteria required for home infusion therapy, a safe and effective alternative to hospital-based administration.

Working collaboratively with the provider, care team, and member, GTRx coordinated a seamless transition to the home infusion setting, and ensuring uninterrupted treatment.



The Result

This site-of-care optimization led to net savings of over \$800,000 for the plan over duration of the patient's treatments without compromising patient safety or outcomes.

Beyond immediate financial savings, this intervention underscores the importance of effective J-code cost management proactive case identification, rapid implementation, and a commitment to smarter specialty drug management.

**MEASURABLE SAVINGS.
IMPROVED OUTCOMES.
RELIABLE PARTNERSHIPS.**

See how GTRx can help your clients unlock savings and improve patient care. Contact GTSN today to learn more.

Hy Byrd
Chief Operating Officer

